Compare Ascendis Pharma A/S (ASND) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Rocket Lab USA Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Rocket Lab USA Inc trades at $80.2 (market cap $50.64B). The key difference: Rocket Lab USA Inc is far larger — about 2.9× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals.
| ASND | RKLB | |
|---|---|---|
Market Cap | $17.74B | $50.64B |
Sector | Health | Technology |
52-Week High | $277.18 | $150.23 |
52-Week Low | $163.32 | $39.03 |
Enterprise Value | $18.11B | $49.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Rocket Lab (RKLB) trades at $81.04, down 1.83% amid broader space sector weakness. The stock shows bearish technical signals with support at $77-$81 levels, while fundamentals reveal strong revenue growth ($602M in 2025) but persistent losses (-$198M net income). Recent news highlights the $8B Iridium acquisition and innovative 'Hungry Hippo' technology, positioning the company for long-term growth in the expanding space economy.
Analyst consensus remains bullish with a $119.10 price target (75% buy ratings), though profitability challenges and high valuations (P/S 66.26) present near-term risks. The company's expansion into satellite communications and defense contracts provides growth catalysts, but investors face volatility from sector-wide valuation concerns and execution risks on major acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
